Related references
Note: Only part of the references are listed.Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension
Ralf Ewert et al.
CLINICAL RESEARCH IN CARDIOLOGY (2017)
Incidence and prevalence of pulmonary arterial hypertension in Germany
Marius M. Hoeper et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Nazzareno Galie et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance
Harrison W. Farber et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2015)
Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: A Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis
Raymond L. Benza et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2015)
Anticoagulation and Survival in Pulmonary Arterial Hypertension Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)
Karen M. Olsson et al.
CIRCULATION (2014)
Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension
Jason S. Fritz et al.
CHEST (2013)
Evaluation of the Predictive Value of a Clinical Worsening Definition Using 2-Year Outcomes in Patients With Pulmonary Arterial Hypertension A REVEAL Registry Analysis
Adaani E. Frost et al.
CHEST (2013)
Definitions and Diagnosis of Pulmonary Hypertension
Marius M. Hoeper et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Treatment Goals of Pulmonary Hypertension
Vallerie V. McLaughlin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Hossein-Ardeschir Ghofrani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension
Sean Gaine et al.
EUROPEAN RESPIRATORY REVIEW (2013)
The Minimal Important Difference in the 6-Minute Walk Test for Patients with Pulmonary Arterial Hypertension
Stephen C. Mathai et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials
Nicole B. Gabler et al.
CIRCULATION (2012)
Do Changes of 6-Minute Walk Distance Predict Clinical Events in Patients With Pulmonary Arterial Hypertension? A Meta-Analysis of 22 Randomized Trials
Gianluigi Savarese et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database
Anthony J. Tyndall et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Predicting Survival in Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
Raymond L. Benza et al.
CIRCULATION (2010)
Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era
Marc Humbert et al.
CIRCULATION (2010)
The role of per cent predicted 6-min walk distance in pulmonary arterial hypertension
W-T. N. Lee et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Estimating a Minimally Important Difference in Pulmonary Arterial Hypertension Following Treatment With Sildenafil
Claire Gilbert et al.
CHEST (2009)
Tadalafil Therapy for Pulmonary Arterial Hypertension
Nazzareno Galie et al.
CIRCULATION (2009)
International, prospective register for the documentation of first-line and maintenance therapy in patients with pulmonary hypertension (CompERA-XL)
D. Pittrow et al.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2009)
Guidelines for the diagnosis and treatment of pulmonary hypertension
Nazzareno Galie et al.
EUROPEAN HEART JOURNAL (2009)
End Points and Clinical Trial Design in Pulmonary Arterial Hypertension
Vallerie V. McLaughlin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association
Vallerie V. McLaughlin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Inflammation, Growth Factors, and Pulmonary Vascular Remodeling
Paul M. Hassoun et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Pulmonary hypertension
Gorev Grubu Uyeleri et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2009)
Ambrisentan for the treatment of pulmonary arterial hypertension -: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
Nazzareno Galie et al.
CIRCULATION (2008)
Gender and age related predictive value of walk test in heart failure: Do anthropometrics matter in clinical practice?
L. Frankenstein et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2008)
Sex-specific predictive power of 6-minute walk test in chronic heart failure is not enhanced using percent achieved of published reference equations
Lutz Frankenstein et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2008)
Sildenafil citrate therapy for pulmonary arterial hypertension
N Galiè et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Ambrisentan therapy for pulmonary arterial hypertension
N Galié et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Sitaxsentan therapy for pulmonary arterial hypertension
RJ Barst et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Cellular and molecular pathobiology of pulmonary arterial hypertension
M Humbert et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Bosentan therapy for pulmonary arterial hypertension
LJ Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
